$50.00 0.8%
RVMD Stock Price vs. AI Score
Data gathered: October 18

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Revolution Medicines

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.


Revolution Medicines
Price $50.00
Target Price Sign up
Volume 888,040
Market Cap $8.18B
Year Range $29 - $50.48
Dividend Yield 0%
Analyst Rating 100% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q2 '24022M-22M-133M-156M-0.810
Q1 '24026M-26M-116M-141M-0.700
Q4 '23690,00036M-36M-162M-176M-1.140
Q3 '23016M-16M-108M-123M-0.990
Q2 '233.8M15M-11M-98M-108M-0.920

Insider Transactions View All

Kelsey Stephen Michael filed to sell 264,408 shares at $50.1.
October 16 '24
Kelsey Stephen Michael filed to sell 267,018 shares at $49.4.
October 16 '24
Cislini Jeff filed to sell 45,634 shares at $50.2.
October 15 '24
Anders Jack filed to sell 98,932 shares at $50.3.
October 15 '24
GOLDSMITH MARK A filed to sell 300,170 shares at $50.4.
October 15 '24

What is the Market Cap of Revolution Medicines?

The Market Cap of Revolution Medicines is $8.18B.

What is the current stock price of Revolution Medicines?

Currently, the price of one share of Revolution Medicines stock is $50.00.

How can I analyze the RVMD stock price chart for investment decisions?

The RVMD stock price chart above provides a comprehensive visual representation of Revolution Medicines' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Revolution Medicines shares. Our platform offers an up-to-date RVMD stock price chart, along with technical data analysis and alternative data insights.

Does RVMD offer dividends to its shareholders?

As of our latest update, Revolution Medicines (RVMD) does not offer dividends to its shareholders. Investors interested in Revolution Medicines should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Revolution Medicines?

Some of the similar stocks of Revolution Medicines are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.